DDInter721 DDInter1628
An anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Fenoprofen {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Fenoprofen {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Fenoprofen {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) CAMK1D
CAMK1D {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fenoprofen {u} (Compound) resembles {v} (Compound) Fenbufen
Fenbufen {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Fenoprofen {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) ZNF451
ZNF451 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Fenoprofen {u} (Compound) resembles {v} (Compound) Labetalol
Labetalol {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Fenoprofen {u} (Compound) resembles {v} (Compound) Atomoxetine
Atomoxetine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fenoprofen {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) regulates {v} (Gene) C2CD2L
C2CD2L {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Fenoprofen {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) KIAA0907
KIAA0907 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Fenoprofen {u} (Compound) resembles {v} (Compound) Naproxen
Naproxen {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Fenoprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Fenoprofen (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Fenoprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by CAMK1D (Gene) and CAMK1D (Gene) is bound by Ruxolitinib (Compound)
Fenoprofen (Compound) resembles Fenbufen (Compound) and Fenbufen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Fenoprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by ZNF451 (Gene) and ZNF451 (Gene) is upregulated by Ruxolitinib (Compound)
Fenoprofen (Compound) resembles Labetalol (Compound) and Labetalol (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Fenoprofen (Compound) resembles Atomoxetine (Compound) and Atomoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Fenoprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) regulates C2CD2L (Gene) and C2CD2L (Gene) is upregulated by Ruxolitinib (Compound)
Fenoprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by KIAA0907 (Gene) and KIAA0907 (Gene) is downregulated by Ruxolitinib (Compound)
Fenoprofen (Compound) resembles Naproxen (Compound) and Naproxen (Compound) binds PTGS2 (Gene) and Naproxen (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)